Download PDF
Semin Reprod Med 2012; 30(02): 152-160
DOI: 10.1055/s-0032-1307423
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Future Developments to Minimize ART Risks

Alicia Marzal
1   Department of Obstetrics and Gynecology, McGill University, Montreal, Quebec, Canada
2   Department of Gynecology and Obstetrics, Hospital Universitario La Fe, Valencia, Spain
,
Hananel Holzer
1   Department of Obstetrics and Gynecology, McGill University, Montreal, Quebec, Canada
,
Togas Tulandi
1   Department of Obstetrics and Gynecology, McGill University, Montreal, Quebec, Canada
› Author Affiliations
Further Information

Publication History

Publication Date:
27 April 2012 (online)

    Permissions and Reprints

Abstract

The most important complications of assisted reproductive techniques are the risk of ovarian hyperstimulation syndrome (OHSS) and the high incidence of multiple pregnancies. Two new strategies are effective in preventing OHSS: the use of anti-müllerian hormone as a marker and the use of dopamine agonists. Genetic markers and vascular endothelial growth factor levels do not predict OHSS. In vitro oocyte maturation treatment should be considered in high responders and in women at risk of OHSS. For prevention of multiple pregnancies, the most effective method is transfer of a single embryo. Preimplantation genetic screening with comparative genomic hybridization, genetic expression of cumulus cells, time-lapse imaging, and respiration rate are emerging technologies for embryo selection that require further study.

Keywords

ART - IVF - OHSS - risk - complication - prevention - risk factor - multiple pregnancies
 

  • References

  • 1 Delvigne A, Rozenberg S. Epidemiology and prevention of ovarian hyperstimulation syndrome (OHSS): a review. Hum Reprod Update 2002; 8 (6) 559-577
    CrossrefPubMedGoogle Scholar
  • 2 Gerris J. Single-embryo transfer versus multiple-embryo transfer. Reprod Biomed Online 2009; 18 (Suppl. 02) 63-70
    CrossrefPubMedGoogle Scholar
  • 3 Ombelet W, De Sutter P, Van der Elst J, Martens G. Multiple gestation and infertility treatment: registration, reflection and reaction—the Belgian project. Hum Reprod Update 2005; 11 (1) 3-14
    CrossrefPubMedGoogle Scholar
  • 4 Delvigne A. Symposium: Update on prediction and management of OHSS. Epidemiology of OHSS. Reprod Biomed Online 2009; 19 (1) 8-13
    CrossrefPubMedGoogle Scholar
  • 5 Binder H, Dittrich R, Hager I , et al. Association of FSH receptor and CYP19A1 gene variations with sterility and ovarian hyperstimulation syndrome. Reproduction 2008; 135 (1) 107-116
    CrossrefPubMedGoogle Scholar
  • 6 Kaiser UB. The pathogenesis of the ovarian hyperstimulation syndrome. N Engl J Med 2003; 349 (8) 729-732
    CrossrefPubMedGoogle Scholar
  • 7 Rizk B. Symposium: Update on prediction and management of OHSS. Genetics of ovarian hyperstimulation syndrome. Reprod Biomed Online 2009; 19 (1) 14-27
    CrossrefPubMedGoogle Scholar
  • 8 Lussiana C, Guani B, Mari C, Restagno G, Massobrio M, Revelli A. Mutations and polymorphisms of the FSH receptor (FSHR) gene: clinical implications in female fecundity and molecular biology of FSHR protein and gene. Obstet Gynecol Surv 2008; 63 (12) 785-795
    CrossrefPubMedGoogle Scholar
  • 9 Smits G, Olatunbosun O, Delbaere A, Pierson R, Vassart G, Costagliola S. Ovarian hyperstimulation syndrome due to a mutation in the follicle-stimulating hormone receptor. N Engl J Med 2003; 349 (8) 760-766
    CrossrefPubMedGoogle Scholar
  • 10 Vasseur C, Rodien P, Beau I , et al. A chorionic gonadotropin-sensitive mutation in the follicle-stimulating hormone receptor as a cause of familial gestational spontaneous ovarian hyperstimulation syndrome. N Engl J Med 2003; 349 (8) 753-759
    CrossrefPubMedGoogle Scholar
  • 11 Montanelli L, Delbaere A, Di Carlo C , et al. A mutation in the follicle-stimulating hormone receptor as a cause of familial spontaneous ovarian hyperstimulation syndrome. J Clin Endocrinol Metab 2004; 89 (3) 1255-1258
    CrossrefPubMedGoogle Scholar
  • 12 De Leener A, Montanelli L, Van Durme J , et al. Presence and absence of follicle-stimulating hormone receptor mutations provide some insights into spontaneous ovarian hyperstimulation syndrome physiopathology. J Clin Endocrinol Metab 2006; 91 (2) 555-562
    PubMedGoogle Scholar
  • 13 Daelemans C, Smits G, de Maertelaer V , et al. Prediction of severity of symptoms in iatrogenic ovarian hyperstimulation syndrome by follicle-stimulating hormone receptor Ser680Asn polymorphism. J Clin Endocrinol Metab 2004; 89 (12) 6310-6315
    CrossrefPubMedGoogle Scholar
  • 14 d'Alva CB, Serafini P, Motta E, Kohek MB, Latronico AC, Mendonca BB. Absence of follicle-stimulating hormone receptor activating mutations in women with iatrogenic ovarian hyperstimulation syndrome. Fertil Steril 2005; 83 (6) 1695-1699
    CrossrefPubMedGoogle Scholar
  • 15 Kerkelä E, Skottman H, Friden B, Bjuresten K, Kere J, Hovatta O. Exclusion of coding-region mutations in luteinizing hormone and follicle-stimulating hormone receptor genes as the cause of ovarian hyperstimulation syndrome. Fertil Steril 2007; 87 (3) 603-606
    CrossrefPubMedGoogle Scholar
  • 16 Weenen C, Laven JS, Von Bergh AR , et al. Anti-Müllerian hormone expression pattern in the human ovary: potential implications for initial and cyclic follicle recruitment. Mol Hum Reprod 2004; 10 (2) 77-83
    CrossrefPubMedGoogle Scholar
  • 17 Fanchin R, Schonäuer LM, Righini C, Frydman N, Frydman R, Taieb J. Serum anti-Müllerian hormone dynamics during controlled ovarian hyperstimulation. Hum Reprod 2003; 18 (2) 328-332
    CrossrefPubMedGoogle Scholar
  • 18 Eldar-Geva T, Ben-Chetrit A, Spitz IM , et al. Dynamic assays of inhibin B, anti-Mullerian hormone and estradiol following FSH stimulation and ovarian ultrasonography as predictors of IVF outcome. Hum Reprod 2005; 20 (11) 3178-3183
    CrossrefPubMedGoogle Scholar
  • 19 La Marca A, Giulini S, Tirelli A , et al. Anti-Müllerian hormone measurement on any day of the menstrual cycle strongly predicts ovarian response in assisted reproductive technology. Hum Reprod 2007; 22 (3) 766-771
    Google Scholar
  • 20 La Marca A, Sighinolfi G, Radi D , et al. Anti-Mullerian hormone (AMH) as a predictive marker in assisted reproductive technology (ART). Hum Reprod Update 2010; 16 (2) 113-130
    CrossrefPubMedGoogle Scholar
  • 21 Lee TH, Liu CH, Huang CC , et al. Serum anti-Müllerian hormone and estradiol levels as predictors of ovarian hyperstimulation syndrome in assisted reproduction technology cycles. Hum Reprod 2008; 23 (1) 160-167
    CrossrefPubMedGoogle Scholar
  • 22 Nardo LG, Gelbaya TA, Wilkinson H , et al. Circulating basal anti-Müllerian hormone levels as predictor of ovarian response in women undergoing ovarian stimulation for in vitro fertilization. Fertil Steril 2009; 92 (5) 1586-1593
    CrossrefPubMedGoogle Scholar
  • 23 Nelson SM, Yates RW, Fleming R. Serum anti-Müllerian hormone and FSH: prediction of live birth and extremes of response in stimulated cycles—implications for individualization of therapy. Hum Reprod 2007; 22 (9) 2414-2421
    CrossrefPubMedGoogle Scholar
  • 24 Broer SL, Dólleman M, Opmeer BC, Fauser BC, Mol BW, Broekmans FJ. AMH and AFC as predictors of excessive response in controlled ovarian hyperstimulation: a meta-analysis. Hum Reprod Update 2011; 17 (1) 46-54
    CrossrefPubMedGoogle Scholar
  • 25 La Marca A, Stabile G, Artenisio AC, Volpe A. Serum anti-Mullerian hormone throughout the human menstrual cycle. Hum Reprod 2006; 21 (12) 3103-3107
    CrossrefPubMedGoogle Scholar
  • 26 Bersinger NA, Wunder D, Birkhäuser MH, Guibourdenche J. Measurement of anti-mullerian hormone by Beckman Coulter ELISA and DSL ELISA in assisted reproduction: differences between serum and follicular fluid. Clin Chim Acta 2007; 384 (1–2) 174-175
    CrossrefPubMedGoogle Scholar
  • 27 Aboulghar M. Symposium: Update on prediction and management of OHSS. Prevention of OHSS. Reprod Biomed Online 2009; 19 (1) 33-42
    CrossrefPubMedGoogle Scholar
  • 28 Buckett W, Chian RC, Tan SL. Can we eliminate severe ovarian hyperstimulation syndrome? Not completely. Hum Reprod 2005; 20 (8) 2367 ; author reply 2367–2368
    PubMedGoogle Scholar
  • 29 Verberg MF, Macklon NS, Nargund G , et al. Mild ovarian stimulation for IVF. Hum Reprod Update 2009; 15 (1) 13-29
    PubMedGoogle Scholar
  • 30 Reinblatt SL, Buckett W. In vitro maturation for patients with polycystic ovary syndrome. Semin Reprod Med 2008; 26 (1) 121-126
    Article in Thieme ConnectPubMedGoogle Scholar
  • 31 Le Du A, Kadoch IJ, Bourcigaux N , et al. In vitro oocyte maturation for the treatment of infertility associated with polycystic ovarian syndrome: the French experience. Hum Reprod 2005; 20 (2) 420-424
    CrossrefPubMedGoogle Scholar
  • 32 Ata B, Togas T. Pathophysiology of ovarian hyperstimulation syndrome and strategies for its prevention and treatment. Expert Rev Obstet Gynecol 2009; 4: 299-311
    CrossrefPubMedGoogle Scholar
  • 33 Lim JH, Yang SH, Chian RC. New alternative to infertility treatment for women without ovarian stimulation. Reprod Biomed Online 2007; 14 (5) 547-549
    CrossrefPubMedGoogle Scholar
  • 34 Lim JH, Yang SH, Xu Y, Yoon SH, Chian RC. Selection of patients for natural cycle in vitro fertilization combined with in vitro maturation of immature oocytes. Fertil Steril 2009; 91 (4) 1050-1055
    CrossrefPubMedGoogle Scholar
  • 35 Huang JY, Chian RC, Tan SL. Ovarian hyperstimulation syndrome prevention strategies: in vitro maturation. Semin Reprod Med 2010; 28 (6) 519-531
    Article in Thieme ConnectPubMedGoogle Scholar
  • 36 Buckett WM, Chian RC, Holzer H, Dean N, Usher R, Tan SL. Obstetric outcomes and congenital abnormalities after in vitro maturation, in vitro fertilization, and intracytoplasmic sperm injection. Obstet Gynecol 2007; 110 (4) 885-891
    CrossrefPubMedGoogle Scholar
  • 37 Söderström-Anttila V, Salokorpi T, Pihlaja M, Serenius-Sirve S, Suikkari AM. Obstetric and perinatal outcome and preliminary results of development of children born after in vitro maturation of oocytes. Hum Reprod 2006; 21 (6) 1508-1513
    CrossrefPubMedGoogle Scholar
  • 38 Cha KY, Chung HM, Lee DR , et al. Obstetric outcome of patients with polycystic ovary syndrome treated by in vitro maturation and in vitro fertilization-embryo transfer. Fertil Steril 2005; 83 (5) 1461-1465
    CrossrefPubMedGoogle Scholar
  • 39 Child TJ, Phillips SJ, Abdul-Jalil AK, Gulekli B, Tan SL. A comparison of in vitro maturation and in vitro fertilization for women with polycystic ovaries. Obstet Gynecol 2002; 100 (4) 665-670
    CrossrefPubMedGoogle Scholar
  • 40 Lim KS, Yoon SH, Lim JH . IVM as an alternative for overresponders; In: Tan SL, Chian RC, Buckett WM, eds. In: In-Vitro Maturation of Human Oocytes: Basic Science to Clinical Application. London, UK: Informa Healthcare; 2007: 345-352
  • 41 Pellicer A, Albert C, Mercader A, Bonilla-Musoles F, Remohí J, Simón C. The pathogenesis of ovarian hyperstimulation syndrome: in vivo studies investigating the role of interleukin-1beta, interleukin-6, and vascular endothelial growth factor. Fertil Steril 1999; 71 (3) 482-489
    CrossrefPubMedGoogle Scholar
  • 42 Gómez R, Simón C, Remohí J, Pellicer A. Vascular endothelial growth factor receptor-2 activation induces vascular permeability in hyperstimulated rats, and this effect is prevented by receptor blockade. Endocrinology 2002; 143 (11) 4339-4348
    CrossrefPubMedGoogle Scholar
  • 43 Pau E, Alonso-Muriel I, Gómez R , et al. Plasma levels of soluble vascular endothelial growth factor receptor-1 may determine the onset of early and late ovarian hyperstimulation syndrome. Hum Reprod 2006; 21 (6) 1453-1460
    CrossrefPubMedGoogle Scholar
  • 44 Ludwig M, Jelkmann W, Bauer O, Diedrich K. Prediction of severe ovarian hyperstimulation syndrome by free serum vascular endothelial growth factor concentration on the day of human chorionic gonadotrophin administration. Hum Reprod 1999; 14 (10) 2437-2441
    CrossrefPubMedGoogle Scholar
  • 45 Nowicka MA, Fritz-Rdzanek A, Grzybowski W, Walecka I, Niemiec KT, Jakimiuk AJ. C-reactive protein as the indicator of severity in ovarian hyperstimulation syndrome. Gynecol Endocrinol 2010; 26 (6) 399-403
    CrossrefPubMedGoogle Scholar
  • 46 Chen CD, Chen HF, Lu HF, Chen SU, Ho HN, Yang YS. Value of serum and follicular fluid cytokine profile in the prediction of moderate to severe ovarian hyperstimulation syndrome. Hum Reprod 2000; 15 (5) 1037-1042
    CrossrefPubMedGoogle Scholar
  • 47 Artini PG, Fasciani A, Monti M, Luisi S, D'Ambrogio G, Genazzani AR. Changes in vascular endothelial growth factor levels and the risk of ovarian hyperstimulation syndrome in women enrolled in an in vitro fertilization program. Fertil Steril 1998; 70 (3) 560-564
    CrossrefPubMedGoogle Scholar
  • 48 Agrawal R, Tan SL, Wild S , et al. Serum vascular endothelial growth factor concentrations in in vitro fertilization cycles predict the risk of ovarian hyperstimulation syndrome. Fertil Steril 1999; 71 (2) 287-293
    CrossrefPubMedGoogle Scholar
  • 49 Gomez R, Gonzalez-Izquierdo M, Zimmermann RC , et al. Low-dose dopamine agonist administration blocks vascular endothelial growth factor (VEGF)-mediated vascular hyperpermeability without altering VEGF receptor 2-dependent luteal angiogenesis in a rat ovarian hyperstimulation model. Endocrinology 2006; 147 (11) 5400-5411
    CrossrefPubMedGoogle Scholar
  • 50 Garcia-Velasco JA. How to avoid ovarian hyperstimulation syndrome: a new indication for dopamine agonists. Reprod Biomed Online 2009; 18 (Suppl. 02) 71-75
    CrossrefPubMedGoogle Scholar
  • 51 Alvarez C, Martí-Bonmatí L, Novella-Maestre E , et al. Dopamine agonist cabergoline reduces hemoconcentration and ascites in hyperstimulated women undergoing assisted reproduction. J Clin Endocrinol Metab 2007; 92 (8) 2931-2937
    CrossrefPubMedGoogle Scholar
  • 52 Carizza C, Abdelmassih V, Abdelmassih S , et al. Cabergoline reduces the early onset of ovarian hyperstimulation syndrome: a prospective randomized study. Reprod Biomed Online 2008; 17 (6) 751-755
    CrossrefPubMedGoogle Scholar
  • 53 Youssef MA, van Wely M, Hassan MA , et al. Can dopamine agonists reduce the incidence and severity of OHSS in IVF/ICSI treatment cycles? A systematic review and meta-analysis. Hum Reprod Update 2010; 16 (5) 459-466
    CrossrefPubMedGoogle Scholar
  • 54 Colao A, Galderisi M, Di Sarno A , et al. Increased prevalence of tricuspid regurgitation in patients with prolactinomas chronically treated with cabergoline. J Clin Endocrinol Metab 2008; 93 (10) 3777-3784
    CrossrefPubMedGoogle Scholar
  • 55 Busso C, Fernández-Sánchez M, García-Velasco JA , et al. The non-ergot derived dopamine agonist quinagolide in prevention of early ovarian hyperstimulation syndrome in IVF patients: a randomized, double-blind, placebo-controlled trial. Hum Reprod 2010; 25 (4) 995-1004
    CrossrefPubMedGoogle Scholar
  • 56 Kol S, Itskovitz-Eldor J. Severe OHSS: yes, there is a strategy to prevent it!. Hum Reprod 2000; 15 (11) 2266-2267
    CrossrefPubMedGoogle Scholar
  • 57 Griesinger G, Diedrich K, Devroey P, Kolibianakis EM. GnRH agonist for triggering final oocyte maturation in the GnRH antagonist ovarian hyperstimulation protocol: a systematic review and meta-analysis. Hum Reprod Update 2006; 12 (2) 159-168
    CrossrefPubMedGoogle Scholar
  • 58 Humaidan P, Bredkjaer HE, Bungum L , et al. GnRH agonist (buserelin) or hCG for ovulation induction in GnRH antagonist IVF/ICSI cycles: a prospective randomized study. Hum Reprod 2005; 20 (5) 1213-1220
    CrossrefPubMedGoogle Scholar
  • 59 Humaidan P, Papanikolaou EG, Tarlatzis BC. GnRHa to trigger final oocyte maturation: a time to reconsider. Hum Reprod 2009; 24 (10) 2389-2394
    CrossrefPubMedGoogle Scholar
  • 60 Humaidan P, Ejdrup Bredkjaer H, Westergaard LG, Yding Andersen C. 1,500 IU human chorionic gonadotropin administered at oocyte retrieval rescues the luteal phase when gonadotropin-releasing hormone agonist is used for ovulation induction: a prospective, randomized, controlled study. Fertil Steril 2010; 93 (3) 847-854
    CrossrefPubMedGoogle Scholar
  • 61 Lainas TG, Sfontouris IA, Zorzovilis IZ, Petsas GK, Lainas GT, Kolibianakis EM. Management of severe early ovarian hyperstimulation syndrome by re-initiation of GnRH antagonist. Reprod Biomed Online 2007; 15 (4) 408-412
    CrossrefPubMedGoogle Scholar
  • 62 Lainas TG, Sfontouris IA, Zorzovilis IZ , et al. Management of severe OHSS using GnRH antagonist and blastocyst cryopreservation in PCOS patients treated with long protocol. Reprod Biomed Online 2009; 18 (1) 15-20
    CrossrefPubMedGoogle Scholar
  • 63 Giles J, Requena A, García-Velasco JA, Pacheco A, Pellicer J, Pellicer A. GnRH analogue for the prevention of ovarian hyperstimulation syndrome: a pilot study. Fertil Steril 2009; 91 (4, Suppl) 1366-1369
    CrossrefPubMedGoogle Scholar
  • 64 Ferraretti AP, Gianaroli L, Magli C, Fortini D, Selman HA, Feliciani E. Elective cryopreservation of all pronucleate embryos in women at risk of ovarian hyperstimulation syndrome: efficiency and safety. Hum Reprod 1999; 14 (6) 1457-1460
    CrossrefPubMedGoogle Scholar
  • 65 Aflatoonian A, Oskouian H, Ahmadi S, Oskouian L. Can fresh embryo transfers be replaced by cryopreserved-thawed embryo transfers in assisted reproductive cycles? A randomized controlled trial. J Assist Reprod Genet 2010; 27 (7) 357-363
    CrossrefPubMedGoogle Scholar
  • 66 D'Angelo A, Amso N. Embryo freezing for preventing ovarian hyperstimulation syndrome. Cochrane Database Syst Rev 2007; (3) CD002806
    PubMedGoogle Scholar
  • 67 Walker MC, Murphy KE, Pan S, Yang Q, Wen SW. Adverse maternal outcomes in multifetal pregnancies. BJOG 2004; 111 (11) 1294-1296
    CrossrefPubMedGoogle Scholar
  • 68 Lukassen HG, Braat DD, Wetzels AM , et al. Two cycles with single embryo transfer versus one cycle with double embryo transfer: a randomized controlled trial. Hum Reprod 2005; 20 (3) 702-708
    CrossrefPubMedGoogle Scholar
  • 69 Thurin A, Hausken J, Hillensjö T , et al. Elective single-embryo transfer versus double-embryo transfer in in vitro fertilization. N Engl J Med 2004; 351 (23) 2392-2402
    CrossrefPubMedGoogle Scholar
  • 70 Mastenbroek S, van der Veen F, Aflatoonian A, Shapiro B, Bossuyt P, Repping S. Embryo selection in IVF. Hum Reprod 2011; 26 (5) 964-966
    CrossrefPubMedGoogle Scholar
  • 71 Zhang X, Jafari N, Barnes RB, Confino E, Milad M, Kazer RR. Studies of gene expression in human cumulus cells indicate pentraxin 3 as a possible marker for oocyte quality. Fertil Steril 2005; 83 (Suppl. 01) 1169-1179
    CrossrefPubMedGoogle Scholar
  • 72 McKenzie LJ, Pangas SA, Carson SA , et al. Human cumulus granulosa cell gene expression: a predictor of fertilization and embryo selection in women undergoing IVF. Hum Reprod 2004; 19 (12) 2869-2874
    CrossrefPubMedGoogle Scholar
  • 73 Assou S, Haouzi D, Mahmoud K , et al. A non-invasive test for assessing embryo potential by gene expression profiles of human cumulus cells: a proof of concept study. Mol Hum Reprod 2008; 14 (12) 711-719
    CrossrefPubMedGoogle Scholar
  • 74 Hamel M, Dufort I, Robert C , et al. Identification of differentially expressed markers in human follicular cells associated with competent oocytes. Hum Reprod 2008; 23 (5) 1118-1127
    CrossrefPubMedGoogle Scholar
  • 75 Harper J, Coonen E, De Rycke M , et al. What next for preimplantation genetic screening (PGS)? A position statement from the ESHRE PGD Consortium Steering Committee. Hum Reprod 2010; 25 (4) 821-823
    CrossrefPubMedGoogle Scholar
  • 76 Mastenbroek S, Scriven P, Twisk M, Viville S, Van der Veen F, Repping S. What next for preimplantation genetic screening? More randomized controlled trials needed?. Hum Reprod 2008; 23 (12) 2626-2628
    CrossrefPubMedGoogle Scholar
  • 77 Hellani A, Abu-Amero K, Azouri J, El-Akoum S. Successful pregnancies after application of array-comparative genomic hybridization in PGS-aneuploidy screening. Reprod Biomed Online 2008; 17 (6) 841-847
    CrossrefPubMedGoogle Scholar
  • 78 Fragouli E, Alfarawati S, Daphnis DD , et al. Cytogenetic analysis of human blastocysts with the use of FISH, CGH and aCGH: scientific data and technical evaluation. Hum Reprod 2011; 26 (2) 480-490
    CrossrefPubMedGoogle Scholar
  • 79 Wong CC, Loewke KE, Bossert NL , et al. Non-invasive imaging of human embryos before embryonic genome activation predicts development to the blastocyst stage. Nat Biotechnol 2010; 28 (10) 1115-1121
    CrossrefPubMedGoogle Scholar
  • 80 Meseguer M, Hilligsøe KM, Pedersen KS , et al. Pregnancy rates after incubation in new time-lapse incubator (embryoscope) providing detailed information about embryo development compared to incubation in a standard incubator. Paper presented at: ASRM Annual Meeting; October 2010; Denver, CO
    PubMedGoogle Scholar
  • 81 Cruz M, Gadea B, Garrido N , et al. Embryo quality, blastocyst and ongoing pregnancy rates in oocyte donation patients whose embryos were monitored by time-lapse imaging. J Assist Reprod Genet 2011; 28 (7) 569-573
    CrossrefPubMedGoogle Scholar
  • 82 Herrero J, Alberto T, Ramsing NB , et al. Linking successful implantation with the exact timing of cell division events obtained by time-lapse system in the embryoscope. Paper presented at: ASRM Annual Meeting; October 2010; Denver, CO
    PubMedGoogle Scholar
  • 83 Leese HJ. What does an embryo need?. Hum Fertil (Camb) 2003; 6 (4) 180-185
    CrossrefPubMedGoogle Scholar
  • 84 Lopes AS, Larsen LH, Ramsing N , et al. Respiration rates of individual bovine in vitro-produced embryos measured with a novel, non-invasive and highly sensitive microsensor system. Reproduction 2005; 130 (5) 669-679
    CrossrefPubMedGoogle Scholar
  • 85 Lopes AS, Madsen SE, Ramsing NB, Løvendahl P, Greve T, Callesen H. Investigation of respiration of individual bovine embryos produced in vivo and in vitro and correlation with viability following transfer. Hum Reprod 2007; 22 (2) 558-566
    PubMedGoogle Scholar
  • 86 Lopes AS, Lane M, Thompson JG. Oxygen consumption and ROS production are increased at the time of fertilization and cell cleavage in bovine zygotes. Hum Reprod 2010; 25 (11) 2762-2773
    CrossrefPubMedGoogle Scholar
  • 87 Tejera A, Herrero J, Ramsing NB , et al. Embryo respiration measurements used for quantification of embryo quality; embryo respiration correlates with ongoing pregnancy and implantation in oocyte donation program. Paper presented at: 26th Annual Meeting of the European Society of Human Reproduction and Embryology; June 27–30, 2010; Rome, Italy
    PubMedGoogle Scholar
  • 88 Morón FJ, de Castro F, Royo JL , et al. Bone morphogenetic protein 15 (BMP15) alleles predict over-response to recombinant follicle stimulation hormone and iatrogenic ovarian hyperstimulation syndrome (OHSS). Pharmacogenet Genomics 2006; 16 (7) 485-495
    CrossrefPubMedGoogle Scholar
  • 89 Gao MZ, Zhao XM, Sun ZG, Hong Y, Zhao LW, Zhang HQ. Endocrine gland-derived vascular endothelial growth factor concentrations in follicular fluid and serum may predict ovarian hyperstimulation syndrome in women undergoing controlled ovarian hyperstimulation. Fertil Steril 2011; 95 (2) 673-678
    CrossrefPubMedGoogle Scholar
  • 90 Lin YH, Hwang JL, Huang LW , et al. Combination of FSH priming and hCG priming for in-vitro maturation of human oocytes. Hum Reprod 2003; 18 (8) 1632-1636
    CrossrefPubMedGoogle Scholar
  • 91 Reinblatt SHH, Son WY, Shalom-Paz E , et al. Optimizing outcomes of IVM treatment cycles-results of a new and improved protocol. Paper presented at: 26th Annual Meeting of the European Society of Human Reproduction and Embryology; June 27–30, 2010; Rome, Italy
    PubMedGoogle Scholar
  • 92 Fadini R, Dal Canto MB, Mignini Renzini M , et al. Effect of different gonadotrophin priming on IVM of oocytes from women with normal ovaries: a prospective randomized study. Reprod Biomed Online 2009; 19 (3) 343-351
    CrossrefPubMedGoogle Scholar
  • 93 Assou S, Haouzi D, De Vos J, Hamamah S. Human cumulus cells as biomarkers for embryo and pregnancy outcomes. Mol Hum Reprod 2010; 16 (8) 531-538
    CrossrefPubMedGoogle Scholar